Angle Plc Affirms Parsotex's Potency in Fetal Abnormalities Detection

Posted by Deeksha on February 1st, 2019

In the light of growing burden of cancer and fetal health ailments, Angle Plc aims to offer precise diagnostic solutions. Market Research Hub (MRH) in its recent report addition under the title, 'ANGLE plc (AGL) - Product Pipeline Analysis, 2018 Update' evaluates ongoing initiatives of Angle Plc in portfolio diversification and pipeline drug development.

Collaborations and Clinical Studies Pertaining Cancer Therapeutics Remain Crucial for Angle Plc.

To achieve significant breakthroughs in curbing fetal anomalies, Angle, has recently affirmed favorable results pertaining the efficacy of Angle's Parsotix, backed by a pilot study. Angle has affirmed Parsotix's potency in determining any kind of abnormality in fetus by studying the blood sample obtained from pregnant mothers. This is a significant milestone in non-invasive prenatal testing. The development is expected to revolutionize fetal health studies in due course, besides positioning Angle plc lucratively on the growth chart of non-invasive clinic diagnosis.

Additionally, the company has also entered into strategic collaborations with leading pharmaceutical companies to further expand its offerings in liquid biopsy diagnosis. The company has partnered with Abbott to gain access to Abbott's PathVysion HER-2 and FISH kits to carry out a study on metastatic breast cancer to attain actionable insights on circulating tumor cell analytical study.

Request for sample copy of this report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2027945

Angle Plc (AGL) Product Pipeline: Report Scope

This elaborate research report on pipeline review of Angle plc (AGL) commences with an elaborate snapshot encompassing vital details on dynamics and trends that influence Angle’s (AGL) investment strategies. Further, the report assesses Angle’s (AGL) market position on the basis of crucial parameters such as its company overview, company facts and developments, product portfolio, range of diagnostic services, as well as recent developments in terms of strategic acquisitions, mergers, and new product launch.

Further in the course of the report, readers are also presented with vital market information on Angle’s (AGL) geographical footprint, employee structure and subsidiaries. In-depth understanding on Angle’s (AGL) existing portfolio as well as pipeline diagnostic services is aimed at offering report readers with ample competitive advantage besides enlightening readers with entry level barriers based on which aspiring market entrants as well as established entities can aptly deliver lucrative business decisions and investment plans to secure a leading stance amidst stiffening competition.

Browse Full Report with TOC@@ https://www.marketresearchhub.com/report/angle-plc-agl-product-pipeline-analysis-2018-update-report.html

In its subsequent sections the report also analyzes Angle’s (AGL) pipeline products, further diversifying pipeline products into broad segments for superlative understanding. By segments, Angle’s product pipeline is classified by equipment type, indication, development stage, and trial status. Further, the report also evaluates each of the pipeline product on the basis of pipeline territory, development stage, regulatory protocol, device class, applications as well as indications, besides including information on launch date estimations. Further, a dedicated chapter on clinical trials encompassing trial name, objective, design, and status has also been documented in the report to derive actionable business insights on product pipeline of Angle plc.

Competitive Landscape: Angle Plc Product Pipeline

In its trailing sections the report also includes crucial details on existing competitive spectrum, highlighting potent competitors along with their company overview, portfolio diversification, winning tactical strategies, as well as recent developments in terms of new product addition, buy-outs, as well as strategic coalitions and product pipeline with their respective status and launch date.